Lloyd Wright {dot} org

German researchers have determined that epigallocatechin-3-gallate (EGCG)—a flavonoid found in green tea—inhibits the hepatitis C virus (HCV) from entering liver cells. Study findings available in the December issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases, suggest that EGCG may offer an antiviral strategy to prevent HCV reinfection following liver transplantation.

(NaturalNews) Milk thistle's use for liver health for 2000 years was
almost lost under Big Pharma's medical monopoly. Fortunately, it has
experienced a revival as an efficacious natural medicine over the last
few decades. And now, recent milk thistle research indicates it may also
be useful for treating cancer.

The Heat Shock Protein Inhibitor Quercetin Attenuates

A molecule found in sharks appears to be able to wipe out human liver viruses, such as hepatitis, new research has found. 

"Sharks are remarkably resistant to viruses," study researcher Michael
Zasloff, of the Georgetown University Medical Center, told LiveScience.
Zasloff discovered the molecule, squalamine, in 1993 in the dogfish
shark, a small- to medium-size shark found in the Atlantic, Pacific, and
Indian Oceans.

"It looked like no other compound that had been described in any animal
or plant before. It was something completely unique," Zasloff said. The
compound is a potent antibacterial and has shown efficacy in treating
human cancers and an eye condition known as macular degeneration, which
causes blindness.

Hepatitis
Autoimmune Hepatitis, Toxic Hepatitis, Hepatitis B, Hepatitis C

Wobenzym in complex therapy of chronic liver diseases
Vasilenko A. M., Svec S. V. Wobenzym in complex therapy of chronic liver diseases. State Medical Academy in Dnepropetrovsk. II National Congress of Rheumatologists in the Ukraine, Kiev, 1997

Current complex therapy of chronic liver diseases focuses on elimination of basic pathogenetic syndroms of the disease. Glucocorticoids (GC) are the most effective in the treatment of chronic autoimmune hepatitis (CAH) and active liver cirrhosis (LC) with a significant autoimmune process. They appear to be effective regulators of immune reaction which suppress antibody production. One of the undesirable side-effects of GC is formation of circulating middle size immune complexes (CIC) which intensify cytolytic syndrom ( 1, 2, 4). One of the main characteristics of CIC - pathogenesity - is mainly determined by the size of complexes. Pathogenesity is caused, among others factors, also by a quantitative relation between antigen and antibody. During overproduction of antibodies against any antigen or in the case of equivalent relation when antigen is fully or partially bound, large CIC are formed. Mild excess of antigen over appropriate antibody (ratio 3:2) leads to a formation of middle sized immune complexes. Insufficient antibody production causes a formation of low molecular weight complexes. Literature data (l, 2, 4) show that cytolysis is higher when middle size CIC prevail. Optimal conditions for middle size CIC formation arise in 2nd - 3rd week of the treatment by big doses of GC. Wide use of GC is limited also by risk of possible side-effects: pathological changes in organs of digestive system and kidney, insufficient anti-inflammatory effect, impossible induction of remission of the disease. All above mentioned facts speak for a necessity to search for new methods to treat chronic liver diseases. Systemic enzyme therapy seems to be one of the prospective options.

Wobenzym is an enzyme preparation originally designed in Germany in the 1960s and is a natural anti-inflammatory with many additional health benefits.

Although its original use was primarily to treat osteoarthritis, studies have revealed that Wobenzym lowers C-reactive protein levels (a marker of chronic infection in the body) on average by 30%!

Hepatitis C is an infectious disease of the liver that can cause miserable symptoms including fatigue, lack of appetite, abdominal pain, nausea and vomiting. Caused by a virus, hepatitis C affects about 200 million people worldwide. In the U.S. alone, one to two percent of the population is infected. Not only can this infectious disease cause scarring of the liver, cirrhosis, and eventually liver failure, but a significant number of people with hepatitis C also develop sometimes fatal liver disease or cancer.

A group of Australian scientists have been able to cure HIV-like infections in mice by boosting their immune systems.

Doctor Marc Pellegrini from Melbourne's Walter and Eliza Hall Institute found a hormone known as Interleukin 7 stimulates the body's response to an infection, causing it to clear the virus.

This process is called immune exhaustion.

"We found that Interleukin 7 boosted the immune response in a pretty profound fashion, such that animals were able to gradually clear the virus without too much collateral tissue damage," Dr Pellegrini said.

Hepatitis C virus (HCV) can breach the blood-brain barrier and infect support cells in the brain, triggering inflammatory changes that ultimately result in damage to neurons, suggests new research published in the open access online journal PLoS One.